Cosmo Pharmaceuticals N.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cosmo Pharmaceuticals N.V.
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
Apparently positive news for two unglamorous indications – acne and allergy – should be balanced against restrictive reimbursement and market fragmentation.
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
- Specialty Pharmaceuticals
- Controlled Release
- Other Names / Subsidiaries
- Aries Group, Ltd
- Aries Pharmaceuticals, Inc.
- Cosmo Technologies Limited
- Cosmo Pharmaceuticals S.p.A.